VYNE

Vyne Therapeutics Inc. (VYNE) | Rumor.io

Vyne Therapeutics

VYNE

Attention (50-day avg)0%

Attention rank (50-day avg)#4,125

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.71

Market capitalization17.1M

Earnings per share-27.6

Dividend yield (TTM)—

Revenue (annual)570K

Net income (annual)-26.5M

Social

What share of all stock conversation is about VYNE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 15

$VYNE's Board of Directors declared a special cash dividend of $0.38 per share in connection with the proposed merger with Yarrow Bioscience.
The merger is expected to be approved at a shareholder meeting, with a dividend payable after the merge.
$VYNE's stock price has been gaining momentum, with some analysts expecting a potential all-day ripper due to the merger and special cash dividend.

Generated by AI

Sentiment

Of the messages about VYNE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	86.98% +6.72
Bearish	—	—	—	13.02% -6.72

Bullish· Dec 18

$VYNE is poised for a continuation of its premarket gains, aiming for a price of $0.85 with sufficient volume.
The company's upcoming merger with Yarrow Bioscience, Inc. has the potential to drive significant price appreciation, with a range to $0.77 and $0.90+.
$VYNE is experiencing increased buying activity, with a potential random spike in trading volume, and is likely to close above $0.60, attracting new buyers.

Bearish· Dec 17

The company's cash reserves are not sufficient to fund operations beyond 2027, considering its quarterly cash burn of $4 to $5 million.
The stock is experiencing a significant short squeeze, with over 2 million shares shorted, which could lead to a sharp price increase.
The stock is facing dilution risks due to a merger agreement, limiting the company's ability to issue new shares and potentially impacting its value.

Generated by AI

Topics

Of the messages about VYNE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	67.1%
Technical Analysis	—	—	—	18.25%
Macro	—	—	—	11.18%
Controversies	—	—	—	0.51%
Analysts	—	—	—	2.7%
Earnings	—	—	—	0.26%

Dec 17

VYNE Therapeutics is merging with Yarrow Bioscience in an all-stock deal, with VYNE holders owning ~3% of the new YARW.
The combined company will focus on YB-101, a potentially first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease, with ~$200m in new financing and a ~$15–17m cash dividend pre-close.
The merger is expected to fund operations into 2028, with a planned U.S. Phase 1b/2b trial for YB-101 in H1 2026 and Phase 1b data expected in H2 2027.

Generated by AI

Community

Of the messages about VYNE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	30.77%
Newcomers	—	—	—	69.23%

Regulars· Dec 17

VYNE Therapeutics and Yarrow Bioscience announce merger agreement, with VYNE expecting to declare a cash dividend to distribute excess net cash of $14.5-$16.5 million.
The combined entity has committed pre-closing financings of $200M, with a cash runway to fund operations into 2028 and plans for a U.S. Phase 1b/2b trial for YB-101 in H1 2026.
VYNE has sufficient cash to fund operations into 2027, with $31.5 million in cash and investments at the end of the third quarter and a quarterly cash burn of $4-$5 million.

Newcomers· Jul 15

The upcoming shareholder meeting to approve the merger with Yarrow Bioscience is seen as a catalyst for VYNE's stock, with some users expecting the merger to be approved today.
A special cash dividend of $0.38 per share has been declared by VYNE, contingent on the merger, which is estimated to be an aggregate of $16.5 million.
The low float of VYNE's stock, with 31.3M shares outstanding, has triggered a low-float alert, with some users expecting the stock to spike in the near future.

Generated by AI

News

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

NEW HAVEN, Conn., August 13, 2026--Yarrow Bioscience reports second quarter 2026 financial results and provides a business update.

1mo agoYahoo Finance

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease

NEW HAVEN, Conn., July 27, 2026--Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the completion of its merger with VYNE Therapeutics Inc. ("VYNE"), and the previously announced private financings totaling approximately $200 million. The combined company will operate as Yarrow Bioscience, Inc., with its shares expected to begin trading on the N

2mo agoYahoo Finance

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its previously announced special cash dividend (the “Cash Dividend”), declared in connection with the terms and conditions of the Agreement and Plan of Merger and Reorganization, entered into on December 17, 2025, as amended (the “Merger Agreement”), with Yarrow Bioscience, Inc. (“Yarrow”) and Yellow Merger Sub Corp., was distributed, in cash, on July 23, 2026 to VYNE’

2mo agoYahoo Finance

VYNE distributes special cash dividend, merger closing delayed

2mo agoInvesting.com

VYNE Therapeutics approves 1-for-50 reverse stock split

2mo agoInvesting.com

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

Aggregate cash dividend of $17.3 million, or approximately $0.40242 per shareNEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has approved a reverse stock split of VYNE’s common stock at a ratio of 1-for-50 in connection with the anticipated closing of the proposed merger (the “Merger”) with Yarrow Bioscience, Inc. (“Yarrow”). The reverse stock split was previously approved by VYNE’s stockholde

2mo agoYahoo Finance

Also Discussed

Investors talking about VYNE also mention

#	Name	Attention
1	Journey Medical Corp. Common StockDERM	0%0
2	Cartesian Therapeutics, Inc.RNAC	0%0
3	OPTN - OptiNose, Inc.	——
4	Surrozen, Inc.SRZN	0%0
5	TScan Therapeutics, Inc.TCRX	0%0
6	SCPH - scPharmaceuticals Inc.	——
7	Aquestive Therapeutics Inc.AQST	0%+0
8	Atif Holdings Ltd.ZBAI	0%0
9	TherapeuticsMD, Inc.TXMD	0%new
10	Senseonics Holdings, Inc.SENS	0%+0

Vyne Therapeutics Inc.

Healthcare
Biotechnology

Vyne Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative dermatology solutions. Primarily focused on the treatment of skin diseases, Vyne Therapeutics leverages its proprietary technologies to address conditions such as acne and rosacea. The company's commitment to advancing dermatological research is evident in its pipeline of therapeutic products that aim to enhance the care and management of skin conditions. By working closely with healthcare professionals and leveraging partnerships within the pharmaceutical industry, Vyne Therapeutics strives to deliver effective treatment options that improve patient outcomes. As an active participant in the biopharmaceutical market, Vyne Therapeutics plays a critical role in advancing dermatological therapies, contributing to the broader medical and healthcare sectors by providing solutions that benefit consumers and practitioners alike.

Website

Location

P.O. BOX 125

Stewartsville, NJ, 08886

United States

Social

What share of all stock conversation is about VYNE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 15

$VYNE's Board of Directors declared a special cash dividend of $0.38 per share in connection with the proposed merger with Yarrow Bioscience.
The merger is expected to be approved at a shareholder meeting, with a dividend payable after the merge.
$VYNE's stock price has been gaining momentum, with some analysts expecting a potential all-day ripper due to the merger and special cash dividend.

Generated by AI

Sentiment

Of the messages about VYNE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	86.98% +6.72
Bearish	—	—	—	13.02% -6.72

Bullish· Dec 18

$VYNE is poised for a continuation of its premarket gains, aiming for a price of $0.85 with sufficient volume.
The company's upcoming merger with Yarrow Bioscience, Inc. has the potential to drive significant price appreciation, with a range to $0.77 and $0.90+.
$VYNE is experiencing increased buying activity, with a potential random spike in trading volume, and is likely to close above $0.60, attracting new buyers.

Bearish· Dec 17

The company's cash reserves are not sufficient to fund operations beyond 2027, considering its quarterly cash burn of $4 to $5 million.
The stock is experiencing a significant short squeeze, with over 2 million shares shorted, which could lead to a sharp price increase.
The stock is facing dilution risks due to a merger agreement, limiting the company's ability to issue new shares and potentially impacting its value.

Generated by AI

Topics

Of the messages about VYNE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	67.1%
Technical Analysis	—	—	—	18.25%
Macro	—	—	—	11.18%
Controversies	—	—	—	0.51%
Analysts	—	—	—	2.7%
Earnings	—	—	—	0.26%

Dec 17

VYNE Therapeutics is merging with Yarrow Bioscience in an all-stock deal, with VYNE holders owning ~3% of the new YARW.
The combined company will focus on YB-101, a potentially first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease, with ~$200m in new financing and a ~$15–17m cash dividend pre-close.
The merger is expected to fund operations into 2028, with a planned U.S. Phase 1b/2b trial for YB-101 in H1 2026 and Phase 1b data expected in H2 2027.

Generated by AI

Community

Of the messages about VYNE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	30.77%
Newcomers	—	—	—	69.23%

Regulars· Dec 17

VYNE Therapeutics and Yarrow Bioscience announce merger agreement, with VYNE expecting to declare a cash dividend to distribute excess net cash of $14.5-$16.5 million.
The combined entity has committed pre-closing financings of $200M, with a cash runway to fund operations into 2028 and plans for a U.S. Phase 1b/2b trial for YB-101 in H1 2026.
VYNE has sufficient cash to fund operations into 2027, with $31.5 million in cash and investments at the end of the third quarter and a quarterly cash burn of $4-$5 million.

Newcomers· Jul 15

The upcoming shareholder meeting to approve the merger with Yarrow Bioscience is seen as a catalyst for VYNE's stock, with some users expecting the merger to be approved today.
A special cash dividend of $0.38 per share has been declared by VYNE, contingent on the merger, which is estimated to be an aggregate of $16.5 million.
The low float of VYNE's stock, with 31.3M shares outstanding, has triggered a low-float alert, with some users expecting the stock to spike in the near future.

Generated by AI

Vyne Therapeutics

Social

Jul 15

Bullish· Dec 18

Bearish· Dec 17

Dec 17

Regulars· Dec 17

Newcomers· Jul 15

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

VYNE distributes special cash dividend, merger closing delayed

VYNE Therapeutics approves 1-for-50 reverse stock split

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

Also Discussed

Vyne Therapeutics Inc.

Company Information

Location

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

VYNE distributes special cash dividend, merger closing delayed

VYNE Therapeutics approves 1-for-50 reverse stock split

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

Also Discussed

Social

Jul 15

Bullish· Dec 18

Bearish· Dec 17

Dec 17

Regulars· Dec 17

Newcomers· Jul 15